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over a 10-year horizon. A National Health Service (NHS) and personal social ser-
vices perspective was considered. The effectiveness of treatment was evaluated 
in terms of Quality Adjusted Life Years (QALYs) and Disability Adjusted Life Years 
(DALYs). Data were sourced from a phase II, placebo controlled trial of bedaquiline, 
NHS reference costs, and the literature. Costs and effectiveness were discounted 
at a rate of 3.5% per annum. Probabilistic and deterministic sensitivity analysis 
was conducted. Results: The total discounted cost per patient on B+BR was 
£107,123, compared with £116,616 for BR. The total discounted QALYs per patient 
were 4.85 for B+BR and 3.81 for BR. The addition of bedaquiline to BR resulted 
in cost-savings of £9,493 and an additional 1.04 QALYs pp over a 10-year period, 
and is therefore considered to be the dominant (less costly and more effective) 
strategy over BR. B+BR remained dominant versus BR in the majority of sensitivity 
analyses, with a 74% probability of being dominant versus BR in the probabilistic 
analysis. ConClusions: In the UK, bedaquiline is likely to be cost-effective and 
cost-saving, compared to the current standard of care for MDR-TB under a range 
of scenarios. Cost-savings over a 10 year period were realized from reductions in 
lengths of hospital stay, which offset bedaquiline drug costs. Bedaquiline remained 
cost-saving in several sensitivity analyses, highlighting the certainty surrounding 
the results of the model. These results also indicate that the B+BR regimen can 
provide significant social economic benefits versus the BR only regimen.
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objeCtives: To evaluate the long-term cost-effectiveness of umeclidinium bromide 
62.5 mcg OD (UMEC) compared to tiotropium bromide 18 mcg OD (TIO) for the 
maintenance treatment of COPD from the UK National Health Service perspec-
tive Methods: We utilized a recently developed, internally and externally validated 
linked equations COPD Cohort disease progression model. The treatment effect, 
expressed as change from baseline in forced expiratory volume in one second (FEV1) 
at 12 and 24 weeks estimated from a Bucher method indirect treatment comparison 
(ITC) analysis following a systematic review. UMEC price was set at parity price of 
£33.5/month to TIO. Model outcomes included exacerbations, life years, quality 
adjusted life years (QALYs) and costs/QALY. The time horizons investigated ranged 
from one to 20 years (lifetime) on a sliding one-year increment. Costs, survival, and 
QALYs after the first year were discounted at a rate of 3.5%. Health care costs were 
obtained from NHS reference costs (2011-12). Sensitivity analyses were performed 
to evaluate the robustness of the model to variations in the underlying input param-
eters and assumptions. Results: The ITC estimated change from baseline in trough 
FEV1 of 18.06mL (95%CI: -19.11, 55.23, p= 0.341) at 12 weeks and 3.97mL (95%CI: 
-38.30, 46.25, p= 0.854) at 24 weeks for UMEC compared with TIO. At price parity, 
UMEC dominated TIO with incremental QALY of 0.0009, incremental life years of 
0.0001 and cost reduction of £4.54. The sensitivity analyses suggested that variation 
in main parameters will not alter the behavior of the comparison between the two 
treatments. ConClusions: At price parity to TIO, UMEC may be considered as a 
cost-effective treatment alternative for maintenance bronchodilator treatment to 
relieve symptoms in patients with COPD in the UK.
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objeCtives: UMEC/VI is a long acting muscarinic agent (LAMA) and long acting beta 
agonist (LABA) combination therapy. This study evaluated the cost-effectiveness of 
UMEC/VI compared to tiotropium (18µg) from the UK National Health Service per-
spective. Methods: A linked equations cohort model developed using the patient 
level data from ECLIPSE study and validated using patient level data from TORCH 
study was used. The baseline patient characteristics were derived from UMEC/VI 
phase IIIa clinical programme and included symptomatic COPD patients. The treat-
ment effect expressed as change from baseline in forced expiratory volume in one 
second (FEV1) at 24 weeks was estimated using 3 tiotropium comparator phase 
IIIa trials and was assumed to last for at least 52 weeks following treatment initia-
tion. Model outcomes included exacerbations, life years, quality adjusted life years 
(QALYs) and costs/QALY. The timeframe for the analysis was patient lifetime and the 
discount rate for costs and outcomes was 3.5%. The price of UMEC/VI was varied to 
estimate the points at which it would be cost effective compared with the current 
standard of care tiotropium. Health care costs were obtained from NHS reference 
costs (2011-12). Results: The random effects meta-analysis estimated treatment 
benefit of 92.17ml (95% CI: 61.52, 122.82; p< 0.001) in FEV1for UMEC/VI compared with 
tiotropium. A lifetime model resulted in 0.009 fewer moderate-severe exacerbations 
per year on UMEC/VI. At parity price (£33.5/month), UMEC/VI dominated tiotro-
pium with a probability of 0.81 for being cost effective at £30,000/QALY threshold. 
The incremental cost effectiveness ratios were £11,080 and £22,178 at 5% and 10% 
price premium to tiotropium, respectively. ConClusions: At an appropriate price, 
UMEC/VI may be considered as a cost-effective treatment alternative for sympto-
matic patients with COPD.
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and severe exacerbations were also evaluated and the costs were set for one single 
event. Results: The total cost of mild COPD was € 26.22, moderate COPD € 30.26, 
severe COPD € 92.04 and for the very severe COPD € 267.64 for 1 patient/3 months. 
Expenses for bronchodilators also vary between different stages of COPD, for mild 
COPD it represented € 17.44, moderate COPD € 109.54, severe COPD € 219.58 and for 
very severe COPD € 206.15. Cost of treating exacerbations were set for one event - for 
moderate exacerbation € 67 and for severe exacerbation € 1060.27. ConClusions: 
In the management of COPD the most expensive are the costs of hospitalization, 
outpatient care and symptomatic treatment. The most costly is the management 
of the very severe COPD and severe exacerbation. This survey can be used as the 
source for cost inputs in pharmacoeconomic studies.
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objeCtives: The objective was to analyze the cost-effectiveness of a national immu-
nization program with pneumococcal conjugate vaccine (PCV): 10-valent pneumo-
coccal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) 
and 13-valent pneumococcal conjugate vaccine (PCV-13) in Romania. Methods: A 
published age stratified, deterministic, and static cohort model is used. This model 
highlights changes in cost and quality adjusted life years (QALYs) over time. Serotype 
specific disease incidence, age stratified disease incidence, mortality in the popu-
lation, vaccine costs and resource utilization costs were obtained from a General 
Practitioner reports database and epidemiological sources. The model compared 
identical immunization programs involving PHiD-CV and PCV-13 vaccines taking the 
payer perspective. A cohort of 201,104 Romanian infants was followed for four years. 
Same net indirect protection for invasive pneumococcal disease (IPD) was assumed 
for both vaccines. Results: With 80% vaccine uptake and 2+1 vaccination schedule, 
PHiD-CV dominated PCV-13 assuming price parity. Vaccination with PHiD-CV versus 
PCV-13 resulted in an offset for the health care budget of £22,948 (the main driver 
of this difference is the decrease in Acute Otitis Media (AOM) related costs – with a 
total of 4,663 cases prevented) and a total of 23 QALYs gained. Sensitivity analyses 
revealed robustness of the model results, confirmed the dominance of PHiD-CV 
over PCV-13 and substantiated model outcome driven by incremental efficacy of 
PHiD-CV in conjunction with high incidence AOM. ConClusions: According to the 
model, implementation of PHiD-CV vaccination program for infants in Romania will 
offer substantial benefits in terms of cost savings and improved health compared 
to an identical vaccination program involving PCV-13. PHiD-CV’s potential to better 
prevent AOM translates into incremental benefits and dominance of PHiD-CV over 
PCV-13 given that their impact on IPD is similar.
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objeCtives: Disease management programs for chronic obstructive pulmonary 
disease (herein, COPD-DM) are currently implemented on a broad scale in the 
Netherlands. However, the evidence about their cost-effectiveness is still inconclusive. 
We aimed to conduct a cost-effectiveness analysis of a COPD-DM program in primary 
care in the Netherlands, called RECODE. In RECODE, a multidisciplinary primary care 
team was trained in motivational interviewing to improve life style, setting-up indi-
vidual care plans, early recognizing and managing of exacerbations, and implement-
ing clinical guidelines. In addition, clinical decision making was supported by audit 
and feedback reports provided by an ICT program and reimbursement of physical 
reactivation by a physiotherapist was provided. Methods: In a two-year cluster-ran-
domized controlled trial (1086 COPD patients, 40 clusters), the COPD-DM program was 
compared to usual care. As part of this trial we conducted a cost-effectiveness analysis 
to relate the effect of the COPD-DM on intermediate and final health outcomes to the 
costs from a health care and a societal perspective. Detailed self-reported health care 
utilization data were collected during the trial-period. Results: The 2-year inter-
vention costs of the training for professionals, the ICT, and the audit and feedback 
reports were estimated to be € 324 per patient. Excluding these costs, the intervention 
group had € 584 (95% CI € 86 to € 1,046) higher health care costs and € 645 (95% CI € 28 to 
€ 1,190) higher costs from the societal perspective compared to the usual care group. 
Health outcomes were similar in both groups, except for 0.04 (95% CI -0.07 to -0.01) 
less quality-adjusted life-years in the intervention group. ConClusions: RECODE 
was not cost-effective during the 2-year follow-up period. This is most likely due to 
the fact that the interventions targeted professionals instead of patients and were 
suboptimally implemented, the relatively mild COPD population, and the national 
reforms in COPD care that affected the usual care group.
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objeCtives: To evaluate the cost-effectiveness of adding bedaquiline to the inten-
sive phase of background regimens (BR) of drugs for multidrug-resistant tuberculosis 
(MDR-TB) in the United Kingdom (UK). Methods: A cohort-based Markov model 
was developed to estimate the incremental cost-effectiveness ratio of bedaqui-
line plus BR (B+BR) versus BR alone (BR) in the treatment of MDR-TB in the UK, 
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that is possible to achieve cost-savings and a potential clinical benefit with the 
fixed dose of IG for Mexican patients with COPD.
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objeCtives: To analyze ambulatory prescribing practice and to assess the cost-
effectiveness of asthma pharmacotherapy in country settings. Methods: It is a 
prospective prescribing practice and cost-effectiveness analysis. During 2008-2011 
were observed 238 patients in Plovdiv region and collected information about their 
ambulatory asthma pharmacotherapy. Prescribed medicines were systematized in 
INN groups of mono and fixed dose combination products. The FEO1 and percentage 
of patients without exacerbation were used as measure of the therapeutic results. 
Incremental cost-effectiveness ratio was calculated and with Tornado diagram was 
explored the sensitivity of the results. Results: Pharmacotherapy with fixed dose 
combination was performed mainly with Beclomethazone/formoterol; Budesonide/
formoterol; and Salmeterol/fluticasone. The monthly cost of pharmacotherapy is 
varying among 35 and 50 Euro. Incremental cost effectiveness ratio is favoring the 
combination Beclomethazone/ formoterol 100/6 mcg with ICER of 324 Euro for addi-
tional increase in FEO1, and 50 Euro ICER for additional patient without exacerba-
tion, although all alternatives are cost-effective because all ICERs fall below the GDP 
per capita. The monotherapy was performed with Beclomethazone, Fluticasone, 
Budesonide, Ciclesonide, and Montelukast. Its monthly cost was among 19 and 40 
Euro. Incremental cost effectiveness ratio is favoring ciclesonide that is a dominant 
alternative as monotherapy for both studies outcomes. Results are sensitive to the 
changes in therapeutic outcomes. ConClusions: The real life therapy follows the 
international guidelines but less fixed dose combinations were prescribed in com-
parison with international recommendations. Beclomethazone/ formoterol fixed 
dose combination and ciclesonide as monotherapy are cost-effective alternatives 
for the observed health care settings.
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objeCtives: Study of clinical efficacy, tolerance and economic indicators of treat-
ment of non-severe CAP by (5-day) course of levofloxacin 750 mg/day vs. the stand-
ard administration of levofloxacin 500 mg/day. Methods: The research included 64 
patients having non-severe CAP with risk factors (administration of antibiotics during 
the preceding 3 months, concomitant diseases), all of them being males. The patients 
were randomized into 2 groups; the 1st group received high-dose therapy of levofloxa-
cin, 750 mg/day within 5 days (Remedia, Simpex-Pharma, India). 2nd group recieved 
levofloxacin 500 mg/day for 7-10 days (Tavanic®, Sanofi-Winthrop Ind.). Efficacy and 
safety were assessed in terms of comprehensive analysis of clinical, laboratory and 
radiological data. For economic analysis, direct medical costs and “costs-efficacy” 
ratios (CER) were calculated. Results: First group included 32 patients with aver-
age age 22.7±1.8 years. Second group consisted of 32 patients with average 21.8±6 
years. Clinical efficacy of high-dose levofloxacin therapy amounted to 96.9%. Average 
duration of antibiotic treatment was 5.2±0.9 days.. Standard regime by levofloxacin 
was efficient in 100% of cases. Radiological resolution was identical in both groups. 
Transient increase of hepatic transaminase activity was present in 3 patients (9.4%). 
In standard group, this adverse event was present in 4 patients (12.5%). Average treat-
ment cost by levofloxacin 750 mg/day amounted to 13.3±6.2 euros (CERLEVO-750= 13.7); 
cost of the standard therapy was 27.2±4.9 euros (CERLEVO-750= 27.2). ConClusions
: Therefore, in terms of clinical efficacy and safety, the high-dose therapy (750 mg/
day) by levofloxacin, in brief course of treatment of patients having non-severe CAP, 
is comparable with the standard regime of treatment (levofloxacin 500 mg/day for 7 
to 10 days); and, is more efficient in economic terms.
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objeCtives: Optimal asthma control has been associated with significant reduc-
tions in mortality, morbidity, and quality of life gains for the patients. Hospital 
Asthma Clinics (ACs) are hospital-based units run by an experienced team com-
posed of a pneumologist and a specialized nurse. Their aim is to provide effective 
treatment and optimal control to asthma patients. However, their impact on dis-
ease control and their cost-effectiveness are unknown. The objective of this study 
is to assess the cost-effectiveness of managing asthma patients in an AC versus 
traditional management. Methods: We designed a case-crossover study using the 
medical records of all patients submitted to one AC in Spain during 2012. We defined 
the case period as 365 days after the first visit to the AC, and the control period as 365 
days before the index date. We calculated changes in relevant disease control indica-
tors and estimated the Incremental Cost Effectiveness Ratio (ICER) for one additional 
controlled patient. Results: The percentage of controlled patients increased from 
41% to 86% (n= 83, mean age was 49 ± 15.2; 66% female). Asthma control test score 
increased from 18.7 ± 4.6 to 22.6 ± 2.3 (p< 0.005), exacerbations decreased by 75% 
(p< 0.005) and FEV1 increased from 81.4% ± 17.5 to 84.4% ± 16.6 (p< 0.05). The use of 
ICS/LABA combinations decreased from 79.5% to 41%. On the contrary, the use of 
other drugs increased: anticholinergics from 3.6% to 16.9%, inhaled corticosteroids 
objeCtives: Asthma is a chronic disorder requires continuous and long term man-
agement. Thus it makes the patient economically week and produces more burden 
on patient. Short acting β 2agonists in pressurized metered dose inhalers and dry 
powdered inhalers are the most commonly prescribed formulations in south Indian 
clinical settings. The present study aims to investigate and to select appropriate 
cost effective formulation of metered dose inhalers (MDR) or dry powdered inhalers 
(DPI) for salbutamol. Methods: It is a prospective comparative study conducted 
among subjects those who were newly diagnosed with asthma. The patients were 
divided into two groups based on the type of inhaler used such as MDI or DPI group. 
All the patients were counseled about the usage of inhalers during their treat-
ment device allotment. Quality of life and FEV 1 were measured at the baseline 
visit. In addition to that data related to direct cost such as medical, laboratory and 
re- hospitalization costs were also measured at baseline. Follow up was done for 
both the groups. Similar to baseline visit quality of life, FEV1 and direct medical costs 
were measured during follow up. Results: The present study results shows that 
there is no significant difference between two groups with regards to demographic 
characteristics. We observed a significant difference in QOL (p < 0.05) and the mean 
score for two treatment devices groups was found to be 55.63 &43.72 respectively. 
There is no significant difference in FEV 1 (p > 0.05) and symptom free days between 
two treatment devices. Average cost effectiveness ratio was calculated and average 
cost effectiveness ratio for MDI were found to be less compared to DPI but statisti-
cally not significant. ConClusions: Overall it was found that efficacy was higher 
in MDI than DPI and cost was equal for both the groups to treat newly diagnosed 
asthma patients with salbutamol.
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objeCtives: To evaluate clinical efficacy, safety and cost-effectiveness of treat-
ment options for mild to moderate community-acquired pneumonia in patients 
with risk factors of poor efficacy (prior administration of antibiotics, comorbidi-
ties), comparing generic levofloxacin (Glevo, Glenmark Pharmaceuticals Ltd.) 
versus original levofloxacin (Tavanic®, Sanofi-Winthrop Ind.) and conventional 
treatment (b-lactam±macrolide). Methods: Patients were randomized to 3 treat-
ment arms. Mean age was 24.3±11.5years. Treatment arm 1 included 61 patient 
administered GLEVO in the dose of 500 mg/day, whereas in the treatment arm 
2 (n= 41) patients were treated with original levofloxacin (Tavanic) in the dose 
of 500mg/day, and 45 patients in the treatment arm 3 received conventional 
therapy. Clinical efficacy and safety were evaluated based on clinical, laboratory 
and radiological data analysis. Cost-effectiveness analysis included calcula-
tion of direct medical expenses and cost-effectiveness ratios (CER). Results: 
Clinical efficacy rate in the treatment arm 1 (Glevo) was98.4%, in the treatment 
arm 2 (Tavanic)–97.6%, whereas conventional therapy efficacy rate was84.4%. 
Adverse event incidence in the treatment arm 1 was 21.3%, in treatment arms 2 
and 3 –14.6% and35.5% respectively. Treatment duration in the Glevo treatment 
arm was8.2±1.4days, in the treatment arm2 –8±1.2, in the conventional therapy 
arm–7.2±2,1 days. Time to radiological resolution of pneumonia was compa-
rable. Mean cost of antibiotic administration cycle and the cost-effectiveness 
ratio in patients administered Glevo was 7.65€ (CERGLEVO = 7.8), in the treatment 
arm 2 – 22.4€ (CERTAV= 22.9), in the conventional therapy arm–10.8€ (CERSTAND= 
12.8). ConClusions: Administration of levofloxacin for mild to moderate com-
munity-acquired pneumonia in patients with risk factors is superior in clinical 
efficacy compared to conventional treatment modalities. Administration of Glevo 
is characterized by favorable cost-effectiveness parameters.
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objeCtives: To perform a cost-effectiveness analysis of Indacaterol/
Glycopyrronium (IG) against tiotropium monotherapy (TM), salmeterol/flutica-
sone (SF) and indacaterol/tiotropium (IT) for COPD patients from the perspective 
of the Mexican Public Healthcare System. Methods: A patient-simulation model 
structured in MS Excel, developed and validated by Asukai et al (2013), allowed us 
to compare IG against tiotropium monotherapy (TM), salmeterol/fluticasone (SF) 
and indacaterol/tiotropium (IT). The effectiveness measures analyzed were life 
years gained and exacerbations avoided based on efficacy data extracted from a 
comprehensive large phase III trial program comprising 11 studies (ILLUMINATE, 
SHINE, BRIGHT, ENLIGHTEN, SPARK, BLAZE, ARISE, BEACON, RADIATE, LANTERN, 
FLAME) with more than 10,000 patients across 52 countries. COPD drug cost, main-
tenance cost and exacerbation cost were estimated for six months duration of 
model cycle, using local prices for public health care institutions and evaluating 
the resources utilization data extracted from a sample of medical records. Lifetime 
horizon was used and a discount rate of 5%. Deterministic and probabilistic sen-
sitivity analysis was performed. Results: Total expected costs per patient were 
US$30,421 and US$31,577 for the comparison IG vs TM respectively; US$28,817 and 
US$28,852 for IG vs SF respectively; US$28,900 and US$34,557 for IG vs IT respec-
tively. IG delivers slightly more life years than comparators, but avoid significantly 
more exacerbations than the other options (1 to 4) which in turn have favorable 
economic impacts. Sensitivity analysis showed that base-case results are robust to 
variations of key model parameters. ConClusions: Indacaterol/ Glycopyrronium 
resulted more effective and less costly than comparators. These results showed 
